Tegwondo – development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent gliomas
H Strik, J.H Buhk, C Bock, M Nitsche, A.L Hoffmann, A Wrede, C Marosi, U Kaiser, M Christmann, B Kaina · Aktuelle Neurologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: We report on activity and feasibility of a rechallenge of recurrent gliomas with temozolomide (TMZ) in a dose-dense 21/28-day regimen and development of a novel 5/7-day schedule. Methods: 40 recurrent glioma-patients received TMZ 100mg/m2 with individual dose adaptation: 21 pts. received 148 cycles day 1–21/28 (18 WHO IV [GBM], 3 WHO III). GBM-pts. had a mean age of 54.4y, median KPS was 60%. Patients with critical blood counts (˜50%) were switched to a 1 5/7-day regimen. Better tolerability led us to treat 19 subsequent patients initially day 1–5/7: 13 GBM, 2 WHO-III, 4 WHO-II; 55.5 y, KPS 70%, tota…
